Jupiter Topco LLC Makes New Investment in Eupraxia Pharmaceuticals Inc. $EPRX

Key Points

• Jupiter Topco LLC acquired 1.046 million Eupraxia Pharmaceuticals shares worth approximately $6.85 million, giving it a 1.61% stake. Several other institutional investors also initiated positions.
• Eupraxia shares opened at $6.68, near the middle of their $5.12–$9.32 52-week range. The company reported a quarterly loss of $0.23 per share, slightly better than the $0.25 analyst estimate.
• Analyst sentiment is mixed but leans positive, with a consensus “Moderate Buy” rating and an $18 price target versus the current share price. Eupraxia is a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases.

Jupiter Topco LLC purchased a new stake in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 1,046,000 shares of the company's stock, valued at approximately $6,851,000. Jupiter Topco LLC owned 1.61% of Eupraxia Pharmaceuticals as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Persistent Asset Partners Ltd acquired a new stake in shares of Eupraxia Pharmaceuticals in the second quarter valued at $25,000. BlackRock Inc. purchased a new stake in Eupraxia Pharmaceuticals during the 2nd quarter worth about $40,000. Aptus Capital Advisors LLC purchased a new stake in Eupraxia Pharmaceuticals during the 4th quarter worth about $76,000. Guardian Wealth Advisors LLC NC acquired a new stake in Eupraxia Pharmaceuticals in the 4th quarter valued at about $76,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in Eupraxia Pharmaceuticals in the 3rd quarter valued at about $71,000.

Eupraxia Pharmaceuticals Stock Performance

Shares of EPRX opened at $6.68 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 16.00 and a quick ratio of 16.00. Eupraxia Pharmaceuticals Inc. has a 1-year low of $5.12 and a 1-year high of $9.32. The stock has a market cap of $434.33 million, a price-to-earnings ratio of -6.55 and a beta of 1.08. The firm has a 50 day simple moving average of $6.60 and a 200-day simple moving average of $7.03.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. Equities analysts forecast that Eupraxia Pharmaceuticals Inc. will post -0.87 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on EPRX shares. Wall Street Zen downgraded Eupraxia Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a research report on Friday, July 17th. Zacks Research upgraded shares of Eupraxia Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Thursday, May 7th. Oppenheimer assumed coverage on shares of Eupraxia Pharmaceuticals in a research report on Thursday, June 25th. They issued an "outperform" rating and a $17.00 price objective on the stock. Finally, Stifel Nicolaus started coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, May 21st. They issued a "buy" rating and a $25.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Eupraxia Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $18.00.

Eupraxia Pharmaceuticals Profile

Eupraxia Pharmaceuticals, Inc NASDAQ: EPRX is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company's core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source